Dare Bioscience Faces Nasdaq Delisting Risk Over Bid Price
Ticker: DARE · Form: 8-K · Filed: Jan 19, 2024 · CIK: 1401914
Complexity: simple
Sentiment: bearish
Topics: delisting, compliance, stock-price, regulatory
TL;DR
**DARE got a delisting notice from Nasdaq for low stock price.**
AI Summary
Dare Bioscience, Inc. (DARE) reported on January 17, 2024, that it received a notice from Nasdaq regarding its failure to meet the minimum bid price requirement for continued listing. This means DARE's stock price has been consistently below $1.00 per share, putting its listing on the Nasdaq exchange at risk. This matters to investors because delisting could reduce the stock's liquidity and make it harder to trade, potentially leading to a further decline in share price.
Why It Matters
A potential delisting from Nasdaq could significantly harm Dare Bioscience's stock liquidity and investor confidence, making it a less attractive investment.
Risk Assessment
Risk Level: high — The company faces a significant risk of delisting from Nasdaq, which could severely impact its stock's tradability and valuation.
Analyst Insight
A smart investor would closely monitor Dare Bioscience's actions to regain Nasdaq compliance, such as a potential reverse stock split, and assess the impact on their investment given the increased risk of delisting.
Key Players & Entities
- Dare Bioscience, Inc. (company) — registrant facing delisting notice
- Nasdaq (company) — exchange issuing delisting notice
- $1.00 (dollar_amount) — minimum bid price requirement
- January 17, 2024 (date) — date of earliest event reported
Forward-Looking Statements
- Dare Bioscience will implement a reverse stock split to regain Nasdaq compliance. (Dare Bioscience, Inc.) — medium confidence, target: 2024-07-17
- The stock price of Dare Bioscience will remain volatile due to delisting concerns. (Dare Bioscience, Inc.) — high confidence, target: 2024-04-17
FAQ
What is the primary reason Dare Bioscience, Inc. filed this 8-K?
Dare Bioscience, Inc. filed this 8-K because it received a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing' from Nasdaq, specifically regarding its failure to meet the minimum bid price requirement.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 17, 2024.
Which stock exchange is Dare Bioscience, Inc. currently listed on and potentially facing delisting from?
Dare Bioscience, Inc. is currently listed on Nasdaq, as indicated by the 'Name of each exchange on which registered Common stock' section and the context of the delisting notice.
What is the Commission File Number for Dare Bioscience, Inc.?
The Commission File Number for Dare Bioscience, Inc. is 001-36395.
What is the business address of Dare Bioscience, Inc. as stated in the filing?
The business address of Dare Bioscience, Inc. is 3655 Nobel Drive, Suite 260, San Diego, CA 92122.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 13 · Accepted 2024-01-19 16:30:23
Key Financial Figures
- $1.00 — ny's common stock was below the minimum $1.00 per share requirement for continued lis
Filing Documents
- form8-k.htm (8-K) — 35KB
- 0001493152-24-003071.txt ( ) — 205KB
- dare-20240117.xsd (EX-101.SCH) — 3KB
- dare-20240117_lab.xml (EX-101.LAB) — 33KB
- dare-20240117_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DAR BIOSCIENCE, INC. Dated: January 19, 2024 By: /s/ Sabrina Martucci Johnson Name: Sabrina Martucci Johnson Title: President and Chief Executive Officer